Aptamer Group

Targeted delivery has been a major stumbling block for RNA therapies. Our CSO, Dr. David Bunka, spoke with SelectScience® about how Optimer technology is offering new solutions for this field. https://lnkd.in/g9PhY_Cc

To prevent birth defects new legislation introduced this week will require flour to be fortified with folic acid. https://lnkd.in/eCJhGsAf Our Optimer binders for folic acid are specific for individual metabolites in the folate pathway and sensitive enough to allow quantification across the clinical range. Download the poster to check out the data: https://lnkd.in/gFG_8cUk

Did you catch our news about advancing the development of an Optimer deliver vehicle for precision medicine? Technology Networks have a great recap here: https://lnkd.in/e2KtkRvJ

Aptamer Group will be at the Anti-Fibrotic Drug Discovery Summit November 19-21! We’d love to see you… 📊 Poster – 3:00-4:00pm, Wednesday, November 20th, 2024. ‘Optimer-targeted gene silencing in primary fibrotic hepatic stellate cells’ 👨 Meet with Mario Cocco our Business Development Manager for the USA to see how Optimers, as antibody alternatives, could offer new solutions in your fibrosis research. 📖 Our recent blog post on liver fibrosis is fantastic reading as you travel to AFDD: https://lnkd.in/ejpSiZTe Register your interest here: https://bit.ly/40OoDG9

🧬 👩🔬 Using cell screens in your aptamer development enhances your validation, can identify new biomarkers and prevents problems with sourcing target material. 👩🔬 🧬 

Our CEO, Arron Tolley, spoke with Zak Mir regarding last week's progression in the development of an Optimer delivery vehicle for a genetic medicines company, to explain Optimer technology and how this deal could impact Aptamer Group. https://lnkd.in/gYNUrZY7

Bad antibodies waste time and resources and have contributed to the ‘reproducibility crisis’ in the biological sciences, potentially slowing the pace of discovery and drug development. https://lnkd.in/eeed7a5P Scientists across industry, government and academia are coming together to help overcome this problem, but there are other solutions out there, such as #aptamers. Aptamers use in vitro discovery, development and manufacture for the highest consistency and performance tuned for target and application. At Aptamer Group, we have 3 target tuned discovery processes we can combine to offer validation of your reagent even within the discovery process. This gives you piece of mind that it will work, and gives you back time and money to get to the root of your research problem faster. https://lnkd.in/gXYFxYve

ICYMI - PharmTech covered this week's news that Aptamer Group have entered the final commercial development with a genetics medicine company. Following validation of the Optimer delivery vehicle in our customer's lab, we're excited to work on the final stage of development of this potential precision medicine. https://lnkd.in/ggaSbCxY

Our CEO, Arron Tolley, spoke with Proactive explaining the significance of yesterday's genetic medicines announcement for Aptamer Group and commenting on our pipeline. https://lnkd.in/gVF5wUwk

Based on excellent targeting specificity, pan-species compatibility and reproducibility of results our partner is progressing a custom Optimer delivery vehicle for therapeutic use to the final stage of commercial development. Find out more: https://lnkd.in/grWuUTPV #APTA #drugdelivery #therapeutics #aptamers